Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache.

Hee Jung Mo Byung-Kun Kim Heui Soo Moon Soo Jin Cho

Published in: The journal of headache and pain (2022)

One 240 mg dose of galcanezumab with/without conventional therapy for the prevention of CH is considered effective and safe in clinical practices, as seen in the clinical trial of galcanezumab.

Keyphrases

clinical trial
healthcare
primary care
open label
room temperature
phase ii
double blind
combination therapy
replacement therapy
smoking cessation